Larixol

Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM) -induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants[1][2].

Product Specifications

CAS Number

[1438-66-0]

Product Name Alternative

(+) -Larixol

UNSPSC

12352211

Hazard Statement

H315, H319, H335

Target

Akt; ERK; Src

Type

Natural Products

Related Pathways

MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/larixol.html

Purity

95.52

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C[C@]12[C@@](C(C)(CCC2)C)([H])[C@H](CC([C@@H]1CC[C@](C)(O)C=C)=C)O

Molecular Formula

C20H34O2

Molecular Weight

306.48

Precautions

H315, H319, H335

References & Citations

[1]Liao HR, et al. Larixol inhibits fMLP-induced superoxide anion production and chemotaxis by targeting the βγ subunit of Gi-protein of fMLP receptor in human neutrophils. Biochem Pharmacol. 2022 Jul;201:115091.|[2]Urban N, et al. Pharmacological inhibition of focal segmental glomerulosclerosis-related, gain of function mutants of TRPC6 channels by semi-synthetic derivatives of larixol. Br J Pharmacol. 2017 Nov;174 (22) :4099-4122.